Coronavirus Drug Favipiravir Safe And Effective: Glenmark Pharma
Amid the speculations of a possible third COVID-19 wave, Indian pharmaceutical giant Glenmark said that it has concluded post-marketing surveillance (PMS) study on Favipiravir (FabiFlu), which is used to treat patients with moderate to mild Coronavirus.
The study analyzed a total of 1,803 in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate coronavirus patients.
According to the company, a total of 1,803 was analysed in July 2020 to find out the safety and efficacy of the Favipiravir drug in mild to moderate COVID-19 patients.
The company has said that the results revealed no fresh security and safety signals or any concerns with the utilization of Favipiravir. However, already-known side effects like weakness, gastritis, diarrhea, vomiting, etc, were found to be mild.
It further added that the time period for fever resolution was 4 days, and for clinical cure, it was 7 days.
Glenmark Pharmaceuticals 19 June last year, got a green signal for the limited emergency use approval from the Drugs Controller General of India for Favipiravir. With this approval, Glenmark became the first Indian oral Favipiravir-approved medication for the treatment of mild to moderate Coronavirus.
Talking about the approval, it was granted to Glenmark as a part of the accelerated approval process, keeping an eye on the emergency situation of the Coronavirus pandemic in India.
Meanwhile, the Pharmaceutical giant has registered a 20.7 per cent increase in total net profit to Rs. 306.53 crore in the first quarter of the current Fiscal Year (FY).
